Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...
Figure 1: (A) Canonical STAT3 activation pathway. (B) WP1066 and TTI-101, examples of small molecule STAT3 inhibitors that are cell penetrant. Pediatric H3K27M-mutant diffuse midline gliomas (DMGs), ...
44 th Annual J.P. Morgan Healthcare Conference Format: Company presentation Date: Thursday, January 15, 2026 Time: 12:00 PM PT Location: California East at The Westin St. Francis ...
HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) will publicly present, for the first time, clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, in relapsed/refractory ...
Vividion Therapeutics Inc. has patented 2-azaspiro [3.3]heptane derivatives acting as signal transducer and activator of transcription 3 (STAT3) inhibitors potentially useful for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback